Introduction
Case reports
Case 1
Case 2
Discussion
Author (year of publication) | Patient age, years | PD-L1 | BRAF | ICI purpose | ICIs | CRT | Outcome | irAE | Reference number |
---|---|---|---|---|---|---|---|---|---|
The present Case 1 | 56 | Negative | Wild | Main therapy for recurrence | Ipilimumab + Nivolumab, 4 Cy; Nivolumab maintenance | Yes | PR | pituitary dysfunction, grade 3; eosinophilic esophagitis | NA |
The present Case 2 | 50 | Negative | Wild | NAC for stage III melanoma | Ipilimumab + Nivolumab, 3 Cy; Nivolumab maintenance | No | CR | Immune-mediated hepatitis, grade 3 | NA |
Schonewolf CA (2022) #1 | 56 | NA | Wild | NAC for localized melanoma | Ipilimumab + Nivolumab, 4 Cy; Nivolumab maintenance | Yes | CR | NA | (7) |
Schonewolf CA (2022) #2 | 80 | NA | Wild | Main therapy for stage IVB melanoma | Pembrolizumab | Yes | PR | NA | (7) |
Tarhini AA (2022) | 40 s | Positive | Wild | Main therapy for locally advanced melanoma | Ipilimumab + Nivolumab, 3 Cy | No | CR | Immune-mediated hepatitis, grade 3 | (8) |
Ishiguro A (2022) | 70 | NA | Wild | Main therapy for localized melanoma | Nivolumab | No | PR | NA | (9) |
Walz D (2022) | 84 | NA | Wild | Main therapy for stage III melanoma | Ipilimumab + Nivolumab, 1 Cy | No | NA | NA | (10) |
Yin P (2022) | 55 | NA | Mutant | Main therapy for recurrence | Tripalimab | Yes | PR | NA | (11) |
Guo N (2021) | 58 | Positive | NA | AC for stage III melanoma | Nivolumab, 6 Cy | No | CR | NA | (12) |
Lambert L (2021) | 54 | NA | NA | Main therapy for recurrence | Pembrolizumab, 4 Cy | No | PR | Polymorphous vitelliform maculopathy | (13) |
Sezen D (2021) | 73 | NA | NA | Main therapy for stage IIICb melanoma | Ipilimumab + Nivolumab, 3 Cy; Nivolumab 18 Cy | Yes | CR | Diarrhea, urethritis | (14) |
Norwood TG (2019) | 54 | NA | NA | Main therapy for recurrence | Ipilimumab + Nivolumab, 3 Cy; Nivolumab maintenance | No | PR | Rash (grade 3), headache, hyponatremia, hypophysitis, colitis | (15) |
Komatsu-Fujii T (2019) | 85 | NA | Wild | Main therapy for recurrence | Nivolumab, 3 Cy; Pembrolizumab, 4 Cy; Ipilimumab 4 Cy | No | PD | NA | (16) |
Raad RA (2017) | 60 | NA | NA | Main therapy for stage III melanoma | Ipilimumab | NA | NA | Pneumonia | (17) |
Mesko S (2017) | 70 | NA | NA | AC for surgical margin-positive melanoma | Ipilimumab, 4 Cy | Yes | CR | Skin reaction | (18) |
Chanal J (2016) | 72 | Negative | Wild | Main therapy for recurrence | Ipilimumab, 4 Cy; Pembrolizumab, 18 Cy | No | CR | NA | (19) |
Sano T (2016) | 70 | NA | NA | Main therapy for stage IVB melanoma | Nivolumab, 3 Cy | No | NA | Pneumonia | (20) |